SummaryKennedy’s first press conference sets the stage for what could be a controversial tenure at HHS. While his pledge to follow the science sounds promising, his history of questioning vaccines and promoting unproven theories about autism has drawn criticism from public health experts.
SummaryWith FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.